World Health Organization : Year 1990, World Health Organization, Hereditary Disease Program Con.Hypo Gl, No. 90.4: Guidelines on the Prevention and Control of Congenital Hypothyroidism

By Harry Hannon, Dr.

Book Id: WPLBN0000081081
Format Type: PDF eBook:
File Size: 1.28 MB
Reproduction Date: 2005

Title:	World Health Organization : Year 1990, World Health Organization, Hereditary Disease Program Con.Hypo Gl, No. 90.4: Guidelines on the Prevention and Control of Congenital Hypothyroidism
Author:	Harry Hannon, Dr.
Volume:
Language:	English
Subject:	Health., Public health, Wellness programs
Collections:	Medical Library Collection, World Health Collection
Historic Publication Date:
Publisher:	World Health Organization


Citation APA MLA Chicago Hannon, Dr, B. H. (n.d.). World Health Organization : Year 1990, World Health Organization, Hereditary Disease Program Con.Hypo Gl, No. 90.4. Retrieved from http://self.gutenberg.org/

Description
Medical Reference Publication

Excerpt
INTRODUCTION Untreated, congenital hypothyroidism has devastating effects on the growth and development of infants. A deficiency in circulating thyroxine is the biochemical defect that causes this disorder. The deficiency in thyroid hormone can be the result of no thyroid gland, incomplete gland development, or inability to synthesize thyroxine because of iodine deficiency. The early detection and treatment of congenital hypothyroidism is essential to prevention of severe irreversible mental retardation and physical deformities. Some features of untreated hypothyroidism are similar to those of cretinism which exists in endemic goiter regions of the world. The diagnosis and treatment of congenital hypothyroidism must happen before three months of age for therapeutic effectiveness. Early clinical diagnosis is difficult, and before newborn screening, most cases of infant hypothyroidism were not detected before three months of age 1 .

Table of Contents
CONTENTS INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . SITUATION ANALYSIS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Rationale for Screening . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Lb Population Characteristics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 Adverse Outcomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 Principal Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 OBJECTIVES AND TARGETS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 APPROACHES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Education . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Specimen Collection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Laboratory Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Follow-up Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Medical Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Screening Programme Modes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 . ' ACTIVITIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 Government Policy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 Routine Procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 Labo.r a. tory Structure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Traln~ng . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Confirmation Testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Quality Assurance 10 Medical Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . l1 , Developing Advisory Committee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Education of Parents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Legal Aspects II Pilot Testing of Programme . . . . . . . . . . . . . . . . . . . . . ..... ..... . . 11 MONITORING AND EVALUATION .................................... 13 COSTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 MANAGEMENT AND OBSTACLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18